Abstract
In humans uric acid (UA) is the end product of degradation of purines. The handling of UA by the renal system is a complex process which is not fully understood. To date, several urate transporters in the renal proximal tubule have been identified. Among them, urate transporter 1 (URAT1) and a glucose transporter 9 (GLUT9) are considered of greater importance, as potential targets for treatment of hyperuricemia and the potential associated cardio-metabolic risk. Therefore, the recognition of the metabolic pathway of UA and elucidation of occurrence of hyperuricemia may provide important insights about the relationship between UA, pre-hypertension (preHT) and the metabolic syndrome (MetS). We also review the available clinical studies in this field, including experimental studies dealing with the mechanisms of UA transport via different transporters, as well as current treatment options for hyperuricemia in patients with MetS, preHT or cardiovascular risk factors.
Keywords: Cardiovascular risk, metabolic syndrome, metabolism, pre-hypertension, uric acid.
Current Vascular Pharmacology
Title:Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome
Volume: 12 Issue: 4
Author(s): Manfredi Rizzo, Milan Obradovic, Milica Labudovic-Borovic, Dragana Nikolic, Giuseppe Montalto, Ali A. Rizvi, Dimitri P. Mikhailidis and Esma R. Isenovic
Affiliation:
Keywords: Cardiovascular risk, metabolic syndrome, metabolism, pre-hypertension, uric acid.
Abstract: In humans uric acid (UA) is the end product of degradation of purines. The handling of UA by the renal system is a complex process which is not fully understood. To date, several urate transporters in the renal proximal tubule have been identified. Among them, urate transporter 1 (URAT1) and a glucose transporter 9 (GLUT9) are considered of greater importance, as potential targets for treatment of hyperuricemia and the potential associated cardio-metabolic risk. Therefore, the recognition of the metabolic pathway of UA and elucidation of occurrence of hyperuricemia may provide important insights about the relationship between UA, pre-hypertension (preHT) and the metabolic syndrome (MetS). We also review the available clinical studies in this field, including experimental studies dealing with the mechanisms of UA transport via different transporters, as well as current treatment options for hyperuricemia in patients with MetS, preHT or cardiovascular risk factors.
Export Options
About this article
Cite this article as:
Rizzo Manfredi, Obradovic Milan, Labudovic-Borovic Milica, Nikolic Dragana, Montalto Giuseppe, Rizvi A. Ali, Mikhailidis P. Dimitri and Isenovic R. Esma, Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome, Current Vascular Pharmacology 2014; 12 (4) . https://dx.doi.org/10.2174/1570161111999131205160756
DOI https://dx.doi.org/10.2174/1570161111999131205160756 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anesthesia Issues in Central Nervous System Disorders
Current Aging Science Dexmedetomidine: A Review of its Use for the Management of Pain, Agitation, and Delirium in the Intensive Care Unit
Current Pharmaceutical Design Effect of Heart Rate on Arterial Stiffness as Assessed by Pulse Wave Velocity
Current Hypertension Reviews Analysis of Homocysteine in Plasma of Rats Exposed to High-fat Diet and Chronic Unpredictable Mild Stress by LC/ESI-MS/MS
Current Analytical Chemistry Emerging Therapies for Diabetic Neuropathy: A Clinical Overview
Current Diabetes Reviews Wet Chemistry Approaches for Synthesis of Gold Nanospheres, Nanorods and Nanostars
Current Nanoscience How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?
Current Pharmaceutical Design Adenosine Receptors: New Therapeutic Targets for Inflammation in Diabetic Nephropathy
Inflammation & Allergy - Drug Targets (Discontinued) LINE-1 Methylation is Associated with an Increased Risk of Ischemic Stroke in Men
Current Neurovascular Research Management of Blood Pressure and Heart Rate in Patients with Diabetes Mellitus
Current Pharmaceutical Design Identifying Structural Features Related to the Biological Activity of a Series of AT1 Antagonists from Fragment-based Drug Design
Protein & Peptide Letters Tako-tsubo Cardiomyopathy: A Review of the Literature
Current Cardiology Reviews The Use of Vitamin D in Respiratory Diseases
Current Respiratory Medicine Reviews Preface
Current Pharmaceutical Design Depression and Cardiovascular Disease: Role of Nitric Oxide
Cardiovascular & Hematological Agents in Medicinal Chemistry Central Arterial Aging and Angiotensin II Signaling
Current Hypertension Reviews Recent Applications of Grape Polyphenols in Foods, Beverages and Supplements
Recent Patents on Food, Nutrition & Agriculture Metabolic Therapy of Heart Failure
Current Pharmaceutical Design The Detection of Adverse Events in Randomized Clinical Trials: Can we Really Say New Medicines are Safe?
Current Drug Safety Synthesis and Biological Evaluation of Some [1,2,4]Triazolo[3,4-b][1,3,4]Thiadiazoles and [1,2,4]Triazolo[3,4-b][1,3,4]Thiadiazines
Letters in Drug Design & Discovery